The FDA in June approved Zmax (azithromycin extended release) by Pfizer for oral suspension, a one-dose treatment for mild to moderate acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP) in adults, according to a company news release.
Zmax delivers a complete course of therapy in a single two-gram dose. During the first 24 hours after a dose of Zmax, three times as much drug reaches patients' tissues than with a standard dose of immediate-release azithromycin, according to the release. This "front loading" of Zmax provides high drug levels earlier in the course of infection when the bacterial burden is likely to be highest, according to the release.
Zmax's technology allows for the release of the medicine in the small intestine instead of the stomach, which results in fewer side effects, according to the release.
Side effects from Zmax were generally mild to moderate. In the pivotal clinical studies, the most common treatment-related adverse reactions in adults were diarrhea/loose stools, nausea, abdominal pain, headache and vomiting.
No comments:
Post a Comment